OLD Category: immuno-oncology

Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer

• Kasikara C. et. al.,

Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells

• Wobser M. et. al.,

MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer

• Weng Y.S. et. al.,

Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation

• Davidson T.B. et al.,

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells

• Simon N et al.,

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

• Schalper K.A. et al.,

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

• Lu L.C. et al.,

Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy

• Ayers M. et. al.,

Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies

• Hoey C. et. al.,

PD-L1 and tumor-associated macrophages in de novo DLBCL

• McCord R. et al.,

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

• Chumsri S et al.,

A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma

• Huang AC et al.,